Survodutide Dosage: The Phase 3 Trial Schedule
Last updated September 27, 2026 · Reviewed by Grey Peptides Editorial Board · ⚠️ Investigational — trial data only
← Survodutide encyclopedia entry · See also: Retatrutide dosage · CagriSema dosage
Survodutide is an investigational drug in Phase 3 trials; it is not approved by the FDA or any regulator. The doses below come only from clinical trials and are administered under medical supervision within those studies. This page is educational — it is not a protocol, and survodutide is not available as an approved medicine.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
The short version
Survodutide (development code BI 456906, from Boehringer Ingelheim and Zealand Pharma) is a GLP-1/glucagon dual receptor agonist. It belongs to the same wave of next-generation metabolic drugs as retatrutide, but with a distinct receptor combination — adding glucagon-receptor activity to GLP-1, which is of particular interest for reducing liver fat. Because it is still in trials, the only meaningful "dose" is the trial dose, and that exists inside a supervised research setting.
The trial dosing approach
Across its development, survodutide has been given once weekly by subcutaneous injection, with a stepwise titration upward to limit the nausea and other gastrointestinal effects common to incretin therapies. The Phase 2 program used target doses in the low-single-digit milligram range and demonstrated roughly 19% weight loss, which placed it among the higher-efficacy investigational agents; the Phase 3 SYNCHRONIZE (obesity) and LIVERAGE (MASH) programs are evaluating it further.
Human study. Source: "Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial" (2024, PMID 38330987); "A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis" (2024, PMID 38847460)
| Parameter | As used in trials |
|---|---|
| Route | Subcutaneous |
| Frequency | Once weekly |
| Titration | Stepwise up-titration |
| Status | Phase 3 (not approved) |
The titration logic is the same as the approved GLP-1 drugs: start low, step up, let the gut adapt. The difference is that survodutide's schedule has not been finalized into an approved label, so any specific milligram targets are trial parameters, not prescribing instructions.
Regulatory status
Survodutide received FDA Fast Track designation in 2021 and Breakthrough Therapy designation in 2024, as Boehringer Ingelheim has reported — a designation that expedites development and review but is not an approval. As of September 27, 2026 it remains investigational: two phase 3 trials, SYNCHRONIZE-1 in obesity (13.0% weight loss at 76 weeks on 6.0 mg, against 5.4% on placebo) and SYNCHRONIZE-MASLD, reported in 2026, and others, including a heart-safety trial, are still running. "Research" survodutide sold outside of trials is not the trial drug and is not quality-assured. See the Regulatory Status Tracker and our retatrutide dosage page for how investigational incretins are framed here.
Frequently asked questions
When might survodutide be approved?
That depends on the Phase 3 readouts and subsequent regulatory filings, which had not produced an approval as of September 27, 2026. Timelines for investigational drugs are uncertain.
Is the glucagon component risky?
Glucagon-receptor agonism is the feature that distinguishes it, and its safety and metabolic effects are precisely what the trials are characterizing — which is why use outside a trial is not advisable.
How does it compare to retatrutide?
Retatrutide is a triple agonist (GLP-1/GIP/glucagon); survodutide is dual (GLP-1/glucagon). Both are investigational. See the retatrutide hub.
Sources
- Boehringer Ingelheim / Zealand Pharma — survodutide (BI 456906) Phase 3 SYNCHRONIZE and LIVERAGE program; FDA Fast Track (2021) and Breakthrough Therapy (2024) designations.
- Le Roux CW, et al. Survodutide Phase 2 obesity trial results.
Medical disclaimer: Education only, not medical advice. Survodutide is investigational and not approved for any use. Trial doses apply only within supervised studies. Consult a licensed clinician.